• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Why Targeting of PSMA Is a Valuable Addition to the Management of Castration-Resistant Prostate Cancer: The Urologist's Point of View.

作者信息

Hadaschik Boris A, Boegemann Martin

机构信息

Department of Urology, University Hospital Essen, Essen, Germany; and

Department of Urology, University Hospital Münster, Münster, Germany.

出版信息

J Nucl Med. 2017 Aug;58(8):1207-1209. doi: 10.2967/jnumed.117.194753. Epub 2017 May 18.

DOI:10.2967/jnumed.117.194753
PMID:28522737
Abstract
摘要

相似文献

1
Why Targeting of PSMA Is a Valuable Addition to the Management of Castration-Resistant Prostate Cancer: The Urologist's Point of View.为何靶向前列腺特异性膜抗原（PSMA）是去势抵抗性前列腺癌治疗的重要补充：泌尿外科医生的观点
J Nucl Med. 2017 Aug;58(8):1207-1209. doi: 10.2967/jnumed.117.194753. Epub 2017 May 18.
2
PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients.基于 PSMA 的治疗策略：mCRPC 患者诊断与治疗的实用分步方法。
Semin Nucl Med. 2020 Jan;50(1):98-109. doi: 10.1053/j.semnuclmed.2019.07.003. Epub 2019 Aug 21.
3
New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.前列腺癌的新策略：用于诊断和治疗的前列腺特异性膜抗原（PSMA）配体。
Clin Cancer Res. 2016 Jan 1;22(1):9-15. doi: 10.1158/1078-0432.CCR-15-0820.
4
Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing Lu-PSMA Therapy.接受镥-PSMA治疗的去势抵抗性转移性前列腺癌患者反应和总生存期的预测因素
J Nucl Med. 2018 Jul;59(7):1033-1034. doi: 10.2967/jnumed.118.209270. Epub 2018 Apr 13.
5
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.225Ac-PSMA-617用于转移性去势抵抗性前列腺癌的PSMA靶向α放射治疗。
J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7.
6
The Ga/Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV values and absorbed dose estimates.镓/镥治疗诊断一体化概念在去势抵抗性前列腺癌的前列腺特异性膜抗原靶向治疗中的应用：标准化摄取值与吸收剂量估计值的相关性
Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800. doi: 10.1007/s00259-016-3609-9. Epub 2017 Jan 12.
7
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.放射性配体疗法治疗转移性去势抵抗性前列腺癌：当前方法。
Radiat Oncol. 2018 May 23;13(1):98. doi: 10.1186/s13014-018-1037-7.
8
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.前列腺癌基金会PSMA导向放射性核素科学工作组会议报告。
Prostate. 2018 Aug;78(11):775-789. doi: 10.1002/pros.23642. Epub 2018 May 1.
9
177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.镥-177 前列腺特异性膜抗原与镥-177 奥曲肽治疗转移性去势抵抗性前列腺癌伴神经内分泌分化
Clin Nucl Med. 2019 Dec;44(12):978-980. doi: 10.1097/RLU.0000000000002824.
10
Lymph Node Response in a Patient With Metastatic Castration-resistant Prostate Cancer Treated With Radium-223.用镭-223治疗的转移性去势抵抗性前列腺癌患者的淋巴结反应
Clin Genitourin Cancer. 2018 Apr;16(2):e397-e401. doi: 10.1016/j.clgc.2017.10.024. Epub 2017 Nov 7.

引用本文的文献

1
Hydrophilic Small Molecules That Harness Transthyretin To Enhance the Safety and Efficacy of Targeted Chemotherapeutic Agents.利用转甲状腺素蛋白的亲水分子提高靶向化疗药物的安全性和疗效。
Mol Pharm. 2019 Jul 1;16(7):3237-3252. doi: 10.1021/acs.molpharmaceut.9b00432. Epub 2019 Jun 13.
2
Recent advances in theranostics and challenges for the future.治疗诊断学的最新进展与未来挑战。
Br J Radiol. 2018 Nov;91(1091):20170893. doi: 10.1259/bjr.20170893. Epub 2018 Mar 29.